Ainslie Calcutt

Gold Coast, QLD, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Subclinical exposure to Streptococcus pyogenes drives the development of long-lived homologous immunity.

Subclinical exposure to Streptococcus pyogenes drives the development of long-lived homologous immunity.

Journal: Nature communications
Published: July 17, 2025

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

Journal: Trials
Published: August 27, 2024

Disruption of IL-17-mediated immunosurveillance in the respiratory mucosa results in invasive Streptococcus pyogenes infection.

Disruption of IL-17-mediated immunosurveillance in the respiratory mucosa results in invasive Streptococcus pyogenes infection.

Journal: Frontiers in immunology
Published: December 07, 2023

Polymeric epitope-based vaccine induces protective immunity against group A Streptococcus.

Polymeric epitope-based vaccine induces protective immunity against group A Streptococcus.

Journal: NPJ vaccines
Published: February 12, 2023

Streptolysin O Deficiency in Streptococcus pyogenes M1T1 covR/S Mutant Strain Attenuates Virulence in In Vitro and In Vivo Infection Models.

Streptolysin O Deficiency in Streptococcus pyogenes M1T1 covR/S Mutant Strain Attenuates Virulence in In Vitro and In Vivo Infection Models.

Journal: mBio
Published: February 06, 2023

Pneumococcal Phasevarions Control Multiple Virulence Traits, Including Vaccine Candidate Expression.

Pneumococcal Phasevarions Control Multiple Virulence Traits, Including Vaccine Candidate Expression.

Journal: Microbiology spectrum
Published: May 10, 2022

A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.

A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.

Journal: Nature communications
Published: July 21, 2021

Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes.

Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes.

Journal: mBio
Published: February 24, 2021

Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.

Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.

Journal: Clinical & translational immunology
Published: December 22, 2020

Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.

Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.

Journal: Scientific reports
Published: October 14, 2020

Erratum: Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Erratum: Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Journal: NPJ vaccines
Published: September 18, 2020

M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Journal: NPJ vaccines
Published: April 07, 2020
Showing 1-12 of 20

Last Updated: 09/26/2026